Levetiracetam

SKU: orb1310850

Description

Levetiracetam is a distinct anticonvulsant used adjunctively for partial seizures. It is widely applied in neuroscience research to study epilepsy mechanisms and synaptic vesicle protein SV2A modulation in both in vivo and in vitro models. Rare cases of drug-induced liver injury with enzyme elevations have been reported.

Research Area

Epigenetics & Chromatin, Metabolism Research, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 102767-28-2
• MW: 170.21
• Purity: 99.86% (May vary between batches)
• Formula: C₈H₁₄N₂O₂
• SMILES: CC[C@H](N1CCCC1=O)C(N)=O
• Target: Calcium Channel,DNA Methyltransferase
• Solubility: DMSO:121.25 mg/mL (712.36 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (11.75 mM);H2O:17 mg/mL (99.88 mM)

Bioactivity

• In Vivo:
  In a cellular assay, CNX-774 targeted residue Cys-481, the ATP-binding site of BTK, thereby inhibiting its activity (IC50: 1-10 nM).
• In Vitro:
  In a cellular assay, CNX-774 targeted residue Cys-481, the ATP-binding site of BTK, thereby inhibiting its activity (IC50: 1-10 nM).

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, MGMT, HDA, Inhibitor, Levetiracetam, glioblastoma, apoptosis, antiepileptic, Calcium Channel, DNAMethyltransferase, DNMTs, DNA Methyltransferase, DNA MTases, DNA methyltransferase (DNMT), chemosensitizer, CalciumChannel, SIB-S1, Temozolomide, SV2A, synaptic, Synaptic vesicle glycoprotein 2A, protein, UCB L 059, UCB L059, UCB L-059, vesicle

Compound Identifiers

PubChem CID

5284583